TELIX Pharmaceuticals Ltd (TLX) — Cash Flow Reinvestment Rate
TELIX Pharmaceuticals Ltd (TLX) has a Cash Flow Reinvestment Rate of 0.36x as of June 2025, reinvesting AU$10.13 Million (capex AU$10.13 Million ) from operating cash flow of AU$27.98 Million. Explore how much does TELIX Pharmaceuticals Ltd reinvest in capital to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
TELIX Pharmaceuticals Ltd Cash Flow Reinvestment Rate (2020–2024)
Historical reinvestment intensity for TELIX Pharmaceuticals Ltd across 3 annual periods. Also explore TLX current and non-current assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for TELIX Pharmaceuticals Ltd (2020–2024)
Year-by-year capital reinvestment analysis for TELIX Pharmaceuticals Ltd. For live market cap and broader valuation context, see TLX stock market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (AUD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 3.93x | AU$169.21 Million | AU$43.03 Million | AU$34.03 Million | ▲ +158.9% |
| 2023 | 1.52x | AU$36.28 Million | AU$23.88 Million | AU$10.79 Million | ▲ +110.7% |
| 2020 | 0.72x | AU$1.41 Million | AU$1.96 Million | AU$322.00K | — |